Embedded Files
교신저자 논문
Kim Y, Cho YE, Lim H, Park H, Hwang S.
SIRT6 mediates sterol-dependent feedback regulation of cholesterol biosynthetic genes in hepatocytes.
Biomolecules & Therapeutics (accepted)
Cho YE, Kim MJ, Kim Y, Lim H, Park Y, Kim S, Kim SJ, Yoo JW, Ryu S, Song P, Hong C, He Y, Lee H, Cho JY, Hwang S.
CXCL6 exacerbates metabolic dysfunction-associated steatohepatitis by suppressing LPIN1-mediated fatty acid oxidation in hepatocytes.
International Journal of Biological Sciences 2026;22(10):5015-5035. [Cover Article]
Kim Y, Hwang S.
Role of sirtuin 6 in the pathogenesis of metabolic dysfunction-associated steatotic liver disease.
Current Issues in Molecular Biology 2026;48(5):435.
Cho YE, Kim Y, Jo H, Lim H, Kim SJ, Lee H, Hwang S.
Sirtuin 6 activator UBCS039 ameliorates hepatic lipogenesis through liver X receptor deacetylation.
International Immunopharmacology 2026;168:115878.
Guan Y, Kim Y, Wang Y, Cho YE, Xiang X, Kim SJ, Yao T, Feng D, Hwang S, Gao B.
Adipocyte death promotes hepatic infiltration of S100A8+ macrophages and steatotic liver disease progression in mice.
Journal of Clinical Investigation 2025;135(21):e190635.
Hwang HJ, Lim H, Yu JS, Jang ES, Nam YS, Lee YJ, Kim EL, Hwang S, Lee SR.
Isolation and characterization of secondary metabolites from a Hydractinia-associated fungus, Penicillium brevicompactum MSW10-1 and their inhibitory effects on hepatic lipogenesis.
Marine Drugs 2025;23(7):275.
Kim Y, Park Y, Rho H, Yao T, Gao B, Hwang S.
Inflammation in MASLD progression and cancer.
JHEP Reports 2025;7(8):101414.
Kim Y, Lim H, Cho YE, Hwang S.
The SIRT6 activator MDL-800 inhibits PPARa and fatty acid oxidation-related gene expression in hepatocytes.
Biomolecules & Therapeutics 2025;33(3):438-446.
Hwang S, Hicks A, Hoo CZ, Kwon YS, Cho YE, Moore J, Gao B.
Novel treatment of acute and acute-on-chronic liver failure: Interleukin-22.
Liver International 2025;45(3):e15619.
Nguyen LH, Cho YE, Kim S, Kim Y, Kwak J, Suh JS, Lee J, Son K, Kim M, Jang ES, Song N, Choi B, Kim J, Tak Y, Hwang T, Jo J, Lee EW, Kim SB, Kim S, Kwon O, Kim S, Lee SR, Lee H, Kim TJ, Hwang S, Yun H.
Discovery of N-Aryl-N′-[4-(aryloxy)cyclohexyl]squaramide-based inhibitors of LXR/SREBP-1c signaling pathway ameliorating steatotic liver disease: Navigating the role of SIRT6 activation.
Journal of Medicinal Chemistry 2024;67(19):17608-17628.
Choi YJ, Kim Y, Hwang S.
Role of neutrophils in the development of steatotic liver disease.
Seminars in Liver Disease 2024;44(3):300-318.
Kwon YS, Cho YE, Kim Y, Koh M, Hwang S.
Dimethyloxalylglycine suppresses SREBP1c and lipogenic gene expressions in hepatocytes independently of HIF1A.
Current Issues in Molecular Biology 2024;46(3):2386-2397.
Cho YE, Kim Y, Kim SJ, Lee H, Hwang S.
Overexpression of interleukin-8 promotes the progression of fatty liver to nonalcoholic steatohepatitis in mice.
International Journal of Molecular Sciences 2023;24(20):15489.
Cho YE, Kwon YS, Hwang S.
Heterogeneous population of macrophages in the development of nonalcoholic fatty liver disease.
Liver Research 2023;7(1):16-25.
Chung KW, Cho YE, Kim SJ, Hwang S.
Immune-related pathogenesis and therapeutic strategies of nonalcoholic steatohepatitis.
Archives of Pharmacal Research 2022;45(4):229-244.
Yang YM, Cho YE, Hwang S.
Crosstalk between oxidative stress and inflammatory liver injury in the pathogenesis of alcoholic liver disease.
International Journal of Molecular Sciences 2022;23(2):774.
200 CITATIONS (Google Scholar, as of February 2026.)
Hwang S, Yun H, Moon S, Cho YE, Gao B.
Role of neutrophils in the pathogenesis of nonalcoholic steatohepatitis.
Frontiers in Endocrinology 2021;12:751802.
기타 논문
41. Roh YK, Ha YS, Kim TK, Kim K, Kim SR, Kim DH, Hwang S, Yang SR, Jang S, Kim SJ.
Anti-obesity effects of pear extract (Pyrus pyrifolia): Clinical implications and therapeutic potential.
International Journal of Stem Cells 2026;19(2):242-255.
40. He Y, Ge S, Ling S, Yang S, Yang F, Liu X, Dong S, Chen Y, Zhang Z, Zhou Y, Hwang S, Kim SJ, Wang P, He Y, Chen Y.
Macrophage NEDD4L restrains liver fibrosis by preventing scar-associated macrophage expansion via ubiquitination of phospho-SMAD3.
International Journal of Biological Sciences 2026;22(7):3304-3321.
39. Azamov B, Shim WS, Lee C, Kang Y, Jo Y, Rethineswaran VK, Muradilaeva S, Hwang S, Ryu S, Bae SS, Kim JH, Moon HY, Song C, Shin JH, Hong C, Lee KM, Song P.
27-hydroxycholesterol inhibits muscle cell viability via mitochondrial dysfunction: Protective role of ROS-induced HIF-1a.
Free Radical Biology and Medicine 2026;249:393-408.
38. Kong JS, Seo SW, Kim T, Moon HR, Yoo JW, Kim MS, Yun H, Hwang S, Hwang ET, Jung Y, Yoon IS.
Physiologically based pharmacokinetic modeling for umbelliferone in rats and humans: impact of extrahepatic phase II metabolism and hepatic/gut first-pass extraction on oral bioavailability and systemic disposition.
Journal of Pharmaceutical Investigation 2026;56:185–202
37. Gao B, Arab JP, Liangpunsakul S, Ding WX, Szabo G, Mehal WZ, Wang H, He Y, Starkel P, Llorente C, Schnabl B, Hwang S, van der Merwe S, Gao Y, Zheng MH, Kim W, George J, Bataller R, Loomba R, Leggio L, Tacke F.
Metabolic dysfunction and alcohol-associated liver disease.
eGastroenterology 2025;3(4):e100319.
36. Yang L, Li W, Chen Y, Ya R, Qian S, Liu L, Hao Y, Zai Q, Xiao P, Hwang S, He Y.
Downregulation of ubiquitous microRNA-320 in hepatocytes triggers RFX1-mediated FGF1 suppression to accelerate MASH progression.
Acta Pharmaceutica Sinica B 2025;15(8):4096-4114.
35. Zhang X, Zhang L, Ji L, Liangpunsakul S, Zhang J, Hong F, Lyu H, Hwang S, Gou C, Jiang Y, Chen X, Li Q, Tong G, Zhang A, Wang J, Li X, Zhang M, Sun X, Li M, Gao Y.
Pien Tze Huang plus entecavir improves hepatic fibrosis in Chinese patients with chronic hepatitis B.
Phytomedicine 2025;142:156741.
34. Lee YH, Lee J, Jeong J, Park K, Baik B, Kwon Y, Kim K, Khim KW, Ji H, Lee JY, Kim K, Kim JW, Dao T, Kim M, Lee TY, Yang YR, Yoon H, Ryu D, Hwang S, Lee H, Nam D, Kim WK, Park NH, Yun H, Choi JH.
Hepatic miR-93 promotes the pathogenesis of metabolic dysfunction-associated steatotic liver disease by suppressing SIRT1.
Metabolism 2025;169:156266
33. Lee J, Kwak D, Kim H, Ullah M, Kim M, Naeem M, Hwang S, Im E, Yoon IS, Jung Y, Yoo JW.
Elucidating a tumor-selective nanoparticle delivery mechanism at the colorectal lumen-tumor interface for precise local cancer therapy.
Small 2025;21(9):e2409994.
32. Ha YS, Kim TK, Heo J, Oh J, Kim SK, Kim J, Lee J, Yang SR, Hwang S, Kim SJ.
Rocaglamide-A mitigates LPS-induced hepatic inflammation by modulating JNK/AP-1 signaling cascade and ROS production in hepatocytes.
Toxicological Research 2025;41(1):47-59.
31. Feng D, Hwang S, Guillot A, Wang Y, Guan Y, Chen C, Maccioni L, Gao B.
Inflammation in alcohol-associated hepatitis: pathogenesis and therapeutic targets
Cellular and Molecular Gastroenterology and Hepatology 2024;18(3):101352.
30. Saparbayeva A, Lee J, Hlaing SP, Kim J, Kwak D, Kim H, Lee EH, Hwang S, Kim MS, Moon HR, Jung Y, Yoo JW.
Ionically bridged dexamethasone sodium phosphate-zinc-PLGA nanocomplex in alginate microgel for the local treatment of ulcerative colitis.
Archives of Pharmacal Research 2023;46(7):646-658.
29. Wang H, Shen H, Seo W, Hwang S.
Experimental models of fatty liver diseases: Status and appraisal.
Hepatology Communications 2023;7(7):e00200.
28. Hwang S, Kim W.
A crystal ball to forecast treatment responsiveness in NAFLD.
Clinical and Molecular Hepatology 2022;28(3):478-480.
27. Kwak J, Kim MJ, Kim S, Park GB, Jo J, Jeong M, Kang S, Moon S, Bang S, An H, Hwang S, Kim MS, Yoo JW, Moon HR, Chang W, Chung KW, Jeong JY, Yun H.
A bioisosteric approach to the discovery of novel N-aryl-N′-[4-(aryloxy)cyclohexyl]squaramide-based activators of eukaryotic initiation factor 2 alpha (eIF2a) phosphorylation.
European Journal of Medicinal Chemistry 2022;239:114501.
26. Ma J, Guillot A, Yang Z, Mackowiak B, Hwang S, Park O, Peiffer BJ, Ahmadi AR, Melo L, Kusumanchi P, Huda N, Saxena R, He Y, Guan Y, Feng D, Sancho-Bru P, Zang M, Cameron AM, Bataller R, Tacke F, Sun Z, Liangpunsakul S, Gao B.
Distinct histopathological phenotypes of severe alcoholic hepatitis suggest different mechanisms driving liver injury and failure.
Journal of Clinical Investigation 2022;132(14):e157780.
25. Rodrigues RM, He Y, Hwang S, Bertola A, Mackowiak B, Ait-Ahmed Y, Seo W, Ma J, Wang X, Park SH, Guan Y, Fu Y, Vanhaecke T, Feng D, Gao B.
E-selectin-dependent inflammation and lipolysis in adipose tissue exacerbate steatosis-to-steatohepatitis progression via S100A8/9.
Cellular and Molecular Gastroenterology and Hepatology 2022;13(1):151-171.
24. Ha YS, Kim TK, Park KS, Hwang S, Kim J, Kim SJ.
Inhibitory effects of Rocaglamide-A on PPARg-driven adipogenesis through regulation of mitotic clonal expansion involving the JAK2/STAT3 pathway.
Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids 2022;1867(6):159148.
23. Hwang S, Chung KW.
Targeting fatty acid metabolism for fibrotic disorders.
Archives of Pharmacal Research 2021;44(9-10):839-856.
22. Hwang S, Yang YM.
Exosomal microRNAs as diagnostic and therapeutic biomarkers in non-malignant liver diseases.
Archives of Pharmacal Research 2021;44(6):574-587.
21. Elsabrouty R, Jo Y, Hwang S, Jun DJ, DeBose-Boyd RA.
Type 1 polyisoprenoid diphosphate phosphatase modulates geranylgeranyl-mediated control of HMG CoA reductase and UBIAD1.
eLife 2021;10:e64688.
20. He Y, Rodrigues RM, Wang X, Seo W, Ma J, Hwang S, Fu Y, Trojnar E, Matyas C, Zhao S, Ren R, Feng D, Pacher P, Kunos G, Gao B.
Neutrophil-to-hepatocyte communication in steatohepatitis via the selective LDLR-dependent extracellular vesicle transfer.
Journal of Clinical Investigation 2021;131(3):e141513.
19. Wang X, Seo W, Park SH, Fu Y, Hwang S, Rodrigues RM, Feng D, Gao B, He Y.
MicroRNA-223 restricts liver fibrosis by inhibiting the TAZ-IHH-GLI2 and PDGF signaling pathways via the crosstalk of multiple liver cell types.
International Journal of Biological Sciences 2021;17(4):1153-1167.
18. He Y, Feng D, Hwang S, Mackowiak B, Wang X, Xiang X, Rodrigues RM, Fu Y, Ma J, Ren T, Ait-Ahmed Y, Xu M, Liangpunsakul S, Gao B.
Interleukin-20 exacerbates acute hepatitis and bacterial infection by downregulating IκBζ target genes in hepatocytes.
Journal of Hepatology 2021;75(1):163-176.
17. He Y,* Hwang S,* Ahmed YA, Feng D, Li N, Ribiero M, Lafdil F, Kisseleva T, Szabo G, Gao B.
Immunopathobiology and therapeutic targets related to cytokines in liver diseases.
Cellular and Molecular Immunology 2021;18(1):18-37.
16. Xiang X, Hwang S, Feng D, Shah VH, Gao B.
Interleukin-22 in alcoholic hepatitis and beyond.
Hepatology International 2020;14(5):667-676.
15. Hwang S,* Ren T,* Gao B.
Obesity and binge alcohol intake are deadly combination to induce steatohepatitis: A model of high-fat diet and binge ethanol intake.
Clinical and Molecular Hepatology 2020;26(4):586-594.
14. Hwang S,* Wang X,* Rodrigues RM, Ma J, He Y, Seo W, Park SH, Kim SJ, Feng D, Gao B.
Protective and detrimental roles of p38a mitogen-activated protein kinase in different stages of nonalcoholic fatty liver disease.
Hepatology 2020;72(3):873-891.
13. Hwang S, He Y, Xiang X, Seo W, Kim SJ, Ma J, Ren T, Park SH, Zhou Z, Feng D, Kunos G, Gao B.
Interleukin-22 ameliorates neutrophil-driven nonalcoholic steatohepatitis through multiple targets.
Hepatology 2020;72(2):412-429. [Cover Article]
12. Ma J, Cao H, Rodrigues RM, Xu M, Ren T, He Y, Hwang S, Feng D, Ren R, Yang P, Liangpunsakul S, Sun J, Gao B.
Chronic-plus-binge alcohol intake induces production of proinflammatory mtDNA-enriched extracellular vesicles and steatohepatitis via ASK1/p38MAPKa-dependent mechanisms.
JCI Insight 2020;5(14):e136496.
11. Hwang S, Feng D, Gao B.
Interleukin-22 acts as a mitochondrial protector.
Theranostics 2020;10(17):7836-7840.
10. Jun DJ, Schumacher MM, Hwang S, Kinch LN, Grishin NV, DeBose-Boyd RA.
Schnyder corneal dystrophy-associated UBIAD1 is defective in MK-4 synthesis and resists autophagy-mediated degradation.
Journal of Lipid Research 2020;61(5):746-757.
9. Xiang X, Feng D, Hwang S, Ren T, Wang X, Trojnar E, Matyas C, Mo R, Shang D, He Y, Seo W, Shah VH, Pacher P, Xie Q, Gao B.
Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice.
Journal of Hepatology 2020;72(4):736-745.
8. Seo W, Gao Y, He Y, Sun J, Xu H, Feng D, Park SH, Cho YE, Guillot A, Ren T, Wu R, Wang J, Kim SJ, Hwang S, Liangpunsakul S, Yang Y, Niu J, Gao B.
ALDH2 deficiency promotes alcohol-associated liver cancer by activating oncogenic pathways via oxidized DNA-enriched extracellular vesicles.
Journal of Hepatology 2019;71(5):1000-1011.
7. Hwang S, Gao B.
How does your fat affect your liver when you drink?
Journal of Clinical Investigation 2019;129(6):2181-2183.
6. He Y, Hwang S, Cai Y, Kim SJ, Xu M, Yang D, Guillot A, Feng D, Seo W, Hou X, Gao B.
MicroRNA-223 ameliorates nonalcoholic steatohepatitis and cancer by targeting multiple inflammatory and oncogenic genes in hepatocytes.
Hepatology 2019;70(4):1150-1167.
5. Kim SJ, Feng D, Guillot A, Dai S, Liu F, Hwang S, Parker R, Seo W, He Y, Godlewski G, Jeong WI, Lin Y, Qin X, Kunos G, Gao B.
Adipocyte death preferentially induces liver injury and inflammation through the activation of chemokine (C-C motif) receptor 2-positive macrophages and lipolysis.
Hepatology 2019;69(5):1965-1982.
4. Jo Y, Hamilton JS, Hwang S, Garland K, Smith GA, Su S, Fuentes I, Neelam S, Thompson BM, McDonald JG, DeBose-Boyd RA.
Schnyder corneal dystrophy-associated UBIAD1 inhibits ER-associated degradation of HMG CoA reductase in mice.
eLife 2019;8:e44396.
3. Hwang S, Nguyen AD, Jo Y, Engelking LJ, Brugarolas J, DeBose-Boyd RA.
Hypoxia-inducible factor 1α activates insulin-induced gene 2 (Insig-2) transcription for degradation of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase in the liver.
Journal of Biological Chemistry 2017;292(22):9382-9393.
2. Hwang S, Hartman IZ, Calhoun LN, Garland K, Young GA, Mitsche MA, McDonald J, Xu F, Engelking L, DeBose-Boyd RA.
Contribution of accelerated degradation to feedback regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and cholesterol metabolism in the liver.
Journal of Biological Chemistry 2016;291(26):13479-13494.
1. Hwahng SH,* Ki SH,* Bae EJ, Kim HE, Kim SG.
Role of adenosine monophosphate-activated protein kinase–p70 ribosomal S6 kinase-1 pathway in repression of liver X receptor-alpha-dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones.
Hepatology 2009;49(6):1913-1925.
Page updated
Google Sites
Report abuse